Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: A systematic review and meta-analysis

Neuropsychopharmacology

Volumn 30, Issue 11, 2005, Pages 1949-1962

  Steen, R Grant ^a   Hamer, Robert M ^a   Lieberman, Jeffrey A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Brain metabolism; First episode schizophrenia; N acetylaspartate

Indexed keywords

CHOLINE; CREATINE; N ACETYLASPARTIC ACID;

BRAIN CORTEX; BRAIN LEVEL; BRAIN METABOLISM; BRAIN TISSUE; CLINICAL TRIAL; CONSENSUS; DATA ANALYSIS; EVALUATION; FRONTAL LOBE; GRAY MATTER; HIPPOCAMPUS; HUMAN; MEASUREMENT; META ANALYSIS; METABOLITE; PATIENT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RELIABILITY; REVIEW; SAMPLE SIZE; SCHIZOPHRENIA; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; WHITE MATTER;

ASPARTIC ACID; BRAIN CHEMISTRY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; SCHIZOPHRENIA; TRITIUM;

EID: 30744443492     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300850     Document Type: Review

References (106)

1. Ando K, Takei N, Matsumoto H, Iyo M, Isoda H, Mori N (2002). Neural damage in the lenticular nucleus linked with tardive dyskinesia in schizophrenia: a preliminary study using proton magnetic resonance spectroscopy. Schizophr Res 57: 273-279.
2. Ariza M, Junque C, Mataro M, Poca MA, Bargallo N, Olondo M et al (2004). Neuropsychological correlates of basal ganglia and medial temporal lobe NAA/Cho reductions in traumatic brain injury. Arch Neurol 61: 541-544.
3. 1H-MRS and tissue segmentation. Schizophr Res 52: 87-99.
4. Barker PB (2001). N-acetyl aspartate - a neuronal maker? Ann Neurol 49: 423-424.
5. Bartha R, Al-Semaan YM, Williamson PC, Drost DJ, Malla AK, Carr TJ et al (1999). A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. Biol Psychiat 45: 1403-1411.
6. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L et al (1997). Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiat 54: 959-965.
7. Bernasconi A, Bernasconi N, Natsume J, Antel SB, Andermann F, Arnold DL (2003). Magnetic resonance spectroscopy and imaging of the thalamus in idiopathic generalized epilepsy. Brain 126: 2447-2454.
8. Bertolino A, Callicott JH, Elman I, Mattay VS, Tedeschi G, Frank JA et al (1998b). Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biol Psychiat 43: 641-648.
9. Bertolino A, Callicott JH, Mattay VS, Weidenhammer KM, Rakow R, Egan MF et al (2001). The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol Psychiat 49: 39-46.
10. Bertolino A, Callicott JH, Nawroz S, Mattay VS, Duyn JH, Tedeschi G et al (1998c). Reproducibility of proton magnetic resonance spectroscopic imaging in patients with schizophrenia. Neuropsychopharmacology 18: 1-9.
11. Bertolino A, Esposito G, Callicott JH, Mattay VS, Van Horn JD, Frank JA et al (2000). Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia. Am J Psychiat 157: 26-33.
12. Bertolino A, Kumra S, Callicott JH, Mattay VS, Lestz RM, Jacobsen L et al (1998a). Common pattern of cortical pathology of childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging. Am J Psychiatr 155: 1376-1383.
13. Bertolino A, Nawroz S, Mattay VS, Barnett AS, Duyn JH, Moonen CTW et al (1996). Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiat 153: 1554-1563.
14. Bertolino A, Sciota D, Brudaglio F, Altamura M, Blasi G, Bellomo A et al (2003). Working memeory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. Am J Psychiatr 160: 483-489.
15. Bertolino A, Weinberger DR (1999). Proton magnetic resonance spectroscopy in schizophrenia. Eur J Radiol 30: 132-141.
16. 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 13: 23-31.
17. Block W, Bayer TA, Tepest R, Traber F, Rietschel M, Muller DJ et al (2000). Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study. Neurosci Lett 289: 147-151.
18. Braus DF, Ende G, Weber-Fahr W, Demirakca T, Henn FA (2001). Favorable effect on neuronal viability in the anterior cingulate gyrus due to long-term treatment with atypical antipsychotics: an MRSI study. Pharmacopsychiatry 34: 251-253.
19. Braus DF, Ende G, Weber-Fahre W, Demirakca T, Tost H, Henn FA (2002). Functioning and neuronal viability of the anterior cingulate neurons following antipsychotic treatment: MR-spectroscopic imaging in chronic schizophrenia. Eur Neuropsychopharm 12: 145-152.
20. Brooks WM, Hodde-Vargas J, Vargas LA, Yeo RA, Ford CC, Hendren RL (1998). Frontal lobe of children with schizophrenia spectrum disorders: a proton magnetic resonance spectroscopy study. Biol Psychiatr 43: 263-269.
21. 1H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: clinical, neurodevelopmental, and cognitive correlates. Biol Psychiatr 36: 792-800.
22. Bustillo JR, Lauriello J, Rowland LM, Jung RE, Petropoulos H, Hart BL et al (2001). Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatr Res Neuroimaging 107: 135-149.
23. Bustillo JR, Lauriello J, Rowland LM, Thomson LM, Petropoulos H, Hammond R et al (2002a). Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophr Res 58: 313-321.
24. Bustillo JR, Rowland LM, Lauriello J, Petropoulos H, Hammond R, Hart B et al (2002b). High choline concentrations in the caudate nucleus in antipsychotic-naïve patients with schizophrenia. Am J Psychiatr 159: 130-133.
25. Callicott JH, Bertolino A, Egan MF, Mattay VS, Langheim FJP, Weinberger DR (2000). Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am J Psychiatr 157: 1646-1651.
26. Callicott JH, Egan MF, Bertolino A, Mattay VS, Langheim FJP, Frank JA et al (1998). Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype. Biol Psychiatr 44: 941-950.
27. Cecil KM, DelBello MP, Sellars MC, Strakowski SM (2003). Proton magnetic resonance spectroscopy of the frontal lobe and cerebellar vermis in children with a mood disorder and a familial risk for bipolar disorder. J Child Adolesc Psychopharmacol 13: 545-555.
28. Cecil KM, Lenkinski RE, Gur RE, Gur RC (1999). Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naïve patients with schizophrenia. Neuropsychopharmacology 20: 131-140.
29. 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naïve, chronic schizophrenia. Acad Radiol 1: 211-216.
30. Choe BY, Suh TS, Shinn KS, Lee CW, Lee C, Paik IH (1996). Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest Radiol 31: 345-352.
31. de Stefano N, Matthews PM, Arnold DL (1995). Reversible decreases in N-acetylaspartate after acute brain injury. Mag Reson Med 34: 721-727.
32. Deicken RF, Eliaz Y, Feiwell R, Schuff N (2001b). Increased thalamic N-acetylaspartate in male patients with familial bipolar I disorder. Psychiatr Res Neuroimag 106: 35-45.
33. Deicken RF, Feiwell R, Schuff N, Soher B (2001a). Evidence for altered cerebellar vermis neuronal integrity in schizophrenia. Psychiatr Res Neuroimagig 107: 125-134.
34. Deicken RF, Johnson C, Eliaz Y, Schuff N (2000). Reduced concentrations of thalamic N-acetylaspartate in male patients with schizophrenia. Am J Psychiatr 157: 644-647.
35. Deicken RF, Pegues M, Amend D (1999). Reduced hippocampal N-acetylaspartate without volume loss in schizophrenia. Schizophr Res 37: 217-223.
36. Deicken RF, Zhou L, Corwin F, Vinogradov S, Weiner MW (1997b). Decreased left frontal lobe N-acetylaspartate in schizophrenia. Am J Psychiatr 154: 688-690.
37. Deicken RF, Zhou L, Schliff N, Fein G, Weiner MW (1998). Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy. Biol Psychiatr 43: 483-488.
38. Deicken RF, Zhou L, Schuff N, Weiner MW (1997a). Proton magnetic resonance spectroscopy of the anterior cingulate region in schizophrenia. Schizophr Res 27: 65-71.
39. 1H MRS) in schizophrenia: investigation of the right and left hippocampus, thalamus, and prefrontal cortex. Schizophr Bull 28: 329-339.
40. Delamillieure P, Fernandez J, Constans JM, Brazo P, Benali K, Abadie P et al (2000). Proton magnetic resonance spectroscopy of the medial prefrontal cortex in patients with deficit schizophrenia: preliminary report. Am J Psychiatr 157: 641-643.
41. Dixon RM, Bradley KM, Budge MM, Styles P, Smith AD (2002). Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain 125: 2332-2341.
42. Dowling C, Bollen AW, Noworolski SM, McDermott MW, Barbaro NM, Day MR et al (2001). Preoperative proton MR spectroscopic imaging of brain tumors and correlation with histopathologic analysis of resection specimens. Am J Neuroradiol 22: 604-612.
43. Eluri R, Paul C, Roemer R, Boyko O (1998). Single-voxel proton magnetic resonance spectroscopy of the pons and cerebellum in patients with schizophrenia: a preliminary study. Psychiatr Res Neuroimaging 84: 17-26.
44. Ende G, Braus DF, Walter S, Henn FA (2001). Lower concentration of thalamic N-acetylaspartate in patients with schizophrenia: a replication study. Am J Psychiatr 158: 1314-1316.
45. 1H-MRSI of the hippocampus, thalamus, and basal ganglia in schizophrenia. Eur Arch Psychiatry Clin Neurosci 253: 9-15.
46. Ende G, Braus DF, Wlater S, Weber-Fahr W, Soher B, Maudsley AA et al (2000). Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia. Schizophr Res 41: 389-395.
47. Fannon D, Simmons A, Tennakoon L, O'Ceallaigh S, Sumich A, Doku V et al (2003). Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naïve patients with schizophrenia. Biol Psychiatr 54: 587-598.
48. Fujimoto T, Nakano T, Takano T, Takeuchi K, Yamada K, Fukuzako T et al (1996). Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia. Biol Psychiatr 40: 14-18.
49. Fukuzako H, Kodama S, Fukuzako T, Yamada K, Doi W, Sato D et al (1999). Subtype-associated metabolite differences in the temporal lobe in schizophrenia detected by proton magnetic resonance spectroscopy. Psychiatr Res Neuroimaging 92: 45-56.
50. Fukuzako H, Takeuchi K, Hokazono Y, Fukuzako T, Yamada K, Hashiguchi T et al (1995). Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report. Psychiatr Res Neuroimaging 61: 193-200.
51. Fukuzako H (2000). Heritability heightens brain metabolite differences in schizophrenia. J Neuropsychiatry Clin Neurosci 12: 95-97.
52. Gadea M, Martinez-Bisbal MC, Marti-Bonmati L, Espert R, Casanova R, Goret F et al (2004). Spectroscopic axonal damage to the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis. Brain 127: 89-98.
53. Galanaud D, Chinot O, Nicoli F, Confort-Gouny S, Le Fur Y, Barrie-Attarian M et al (2003). Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J Neurosurg 98: 269-276.
54. Gimenez M, Junque C, perez M, Vendrell P, Baeza I, Salamero M et al (2003). Basal ganglia N-acetylaspartate correlates with the performance in the procedural task 'Tower of Hanoi' of neuroleptic-naïve schizophrenic patients. Neurosci Lett 347: 97-100.
55. Guerrini L, Lolli F, Ginestroni A, Belli G, Della Nave RD, Tessa C et al (2004). Brainstem neurodegeneration correlates with clinical dysfunction in SCA1 but not SCA2. A quantitative volumetric, diffusion and proton spectroscopy MR study. Brain 127: 1785-1795.
56. Hagino H, Suzuki M, Mori K, Nohara S, Yamashita I, Takahashi T et al (2002). Proton magnetic resonance spectroscopy of the inferior frontal gyrus and thalamus and its relationship to verbal learning task performance in patients with schizophrenia: a preliminary report. Psychaitr Clin Neurosci 56: 499-507.
57. Heimberg C, Komoroski RA, Lawson WB, Cardwell D, Karson CN (1998). Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of the drug effect. Psychiatr Res Neuroimaging 83: 105-115.
58. Kalra S, Cashman NR, Genge A, Arnold DL (1998). Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 9: 1757-1761.
59. Kegeles L, Humaran TJ, Mann JJ (1998). In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biol Psychiatr 44: 382-398.
60. Kegeles LS, Shungu DC, Anjilvel S, Chan S, Ellis SP, Xanthopoulos E et al (2000). Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. Psychiatr Res Neuroimaging 98: 163-175.
61. 1H MR spectroscopy. Mag Reson Imaging 22: 721-725.
62. Lim KO, Adalsteinsson E, Spielman D, Sullivan EV, Rosenbloom MJ, Pfefferbaum A (1998). Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Arch Gen Psychiatr 55: 346-352.
63. Lyoo IK, Renshaw PF (2002). Magnetic resonance spectroscopy: current and future applications in psychiatric research. Biol Psychiatr 51: 195-207.
64. Maier M, Ron MA, Barker GJ, Tofts PS (1995). Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia. Psychol Med 25: 1201-1209.
65. Maier M, Ron MA (1996). Hippocampal age-related changes in schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res 22: 5-17.
66. Martin E, Capone A, Schneider J, Hennig J, Thiel T (2001). Absence of N-acetylaspartate in the human brain: impact on neurospectroscopy? Ann Neurol 49: 518-521.
67. Mascalchi M, Belli G, Guerrini L, Nistri M, Del Sappia I, Vallari N (2002). Proton MR spectroscopy of Wernicke encephalopathy. Am J Neuroradiol 23: 1803-1806.
68. Matalon R, Michals K, Kaul R (1995). Canavan disease: from spongy degeneration to molecular analysis. J Pediatr 127: 511-517.
69. 1H magnetic resonance spectroscopic imaging. Neurology 43: 509-515.
70. Miller SP, McQuillen PS, Vigneron DB, Glidden DV, Barkovich AJ, Ferriero DM et al (2004). Preoperative brain injury in newborns with transposition of the great arteries. Ann Thorac Surg 77: 1698-1706.
71. Moore CM, Bonello CM, Sherwood AR, Cohen BM, Renshaw PF, Yurgulen-Todd DA (2002). Mesial temporal lobe Cho to Cr(PRc) ratio asymmetry in chronic schizophrenics. Schizophr Res 57: 35-42.
72. 1H-MRS measurements in schizophrenic patients. Mag Reson Med 50: 704-707.
73. Murphy DG, Critchley HD, Schmitz N, McAlonan G, Van Amelsvoort T, Robertson D et al (2002). Asperger syndrome: a proton magnetic resonance spectroscopy study of brain. Arch Gen Psychiatr 59: 885-891.
74. 1H MRS) of the hippocampal formation in schizophrenia: a pilot study. Br J Psychiatr 165: 481-485.
75. Ohara K, Isoda H, Suzuki Y, Takehara Y, Ochiai M, Takeda H et al (2000). Proton magnetic resonance spectroscopy of lenticular nuclei in simple schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatr 24: 507-519.
76. Omori M, Murata T, Kimura H, Koshimoto Y, Kado H, Ishimori Y et al (2000). Thalamic abnormalities in patients with schizophrenia revealed by proton magnetic resonance spectroscopy. Psychiatr Res Neuroimaging 98: 155-162.
77. 1H-magnetic resonance spectroscopy of postmortem brains with schizophrenia. Biol Psychiatr 42: 359-366.
78. 1H MRSI evidence of metabolic abnormalities in childhood-onset schizophrenia. Neuroimage 21: 1781-1789.
79. Pavlakis SG, Kingsley PB, Harper R, Buckwald S, Spinazzola R, Frank Y et al (1999). Correlation of basal ganglia magnetic resonance spectroscopy with Apgar score in perinatal asphyxia. Arch Neurol 56: 1476-1481.
80. Renshaw PF, Yurgelun-Todd DA, Tohen M, Gruber S, Cohen BM (1995). Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. Am J Psychiatr 152: 444-446.
81. Richards TL (1991). Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring progression, and evaluating therapy. Am J Roentgenol 157: 1073-1078.
82. 1H MRS changes in Huntington's disease. Neurology 53: 806-812.
83. Schuff N, Capizzano AA, Du AT, Amend DL, O'Neill J, Norman D et al (2003). Different patterns of N-acetylaspartate loss in subcortical ischemic vascular dementia and AD. Neurology 61: 358-364.
84. Sharma R, Venkatasubramanian PN, Barany M, Davis JM (1992). Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophr Res 8: 43-49.
85. Shenton ME, Dickey CC, Frumin M, McCarley RW (2001). A review of MRI findings in schizophrenia. Schizophr Res 49: 1-52.
86. Shimizu H, Shirane R, Fujiwara S, Takahashi A, Yoshimoto T (1997). Proton magnetic resonance spectroscopy in children with moya-moya disease. Clin Neurol Neurosurg 99: S64-S67.
87. Shioiri T, Hamakawa H, Kato T, Murashita J, Fujii K, Inubushi T et al (1996). Proton magnetic resonance spectroscopy of the basal ganglia in patients with schizophrenia: a preliminary report. Schizophr Res 22: 19-26.
88. Sigmundsson T, Maier M, Toone BK, Williams SCR, Simmons A, Greenwood K et al (2003). Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res 64: 63-71.
89. Spaniel F, Hajek T, Tintera J, Harantova P, Dezortova M, Hajek M (2003). Differences in fMRI and MRS in a monozygotic twin pair discordant for schizophrenia (case report). Acta Psychiatr Scand 107: 155-158.
90. Stanley JA, Williamson PC, Drost DJ, Rylett RJ, Carr TJ, Malla A et al (1996). An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr Bull 22: 597-609.
91. 1H MRS) in schizophrenic subjects and normal controls. Psychiatr Res Neuroimaging 106: 161-170.
92. Steen RG, Ogg RJ (2005). Abnormally high levels of brain N-acetylaspartate in children with sickle cell disease. Am J Neuroradiol 26: 463-468.
93. Takanashi J, Inoue K, Tomita M, Kurihara A, Morita F, Ikehira H et al (2002). Brain N-acety-laspartate is elevated in Pelizaeus-Merzbacher disease with PLP1 duplication. Neurology 58: 237-241.
94. Tartaglia MC, Narayanan S, Francis SJ, Santos AC, De Stefano N, Lapierre Y et al (2004). The relationship between diffuse axonal damage and fatigue in multiple sclerosis. Arch Neurol 61: 201-207.
95. Taylor JS, Ogg RJ, Langston JW (1998). Proton MR spectroscopy of pediatric brain tumors. Neuroimag Clin N Am 8: 753-779.
96. Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N et al (2003). Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy controls measured with 4.0 T proton MRS. Am J Psychiatr 160: 2231-2233.
97. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J et al (2002). Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatr 159: 1944-1946.
98. 1H MR spectroscopy in childhood-onset schizophrenia. J Magn Reson Imag 8: 841-846.
99. 1H-MRS) of the cerebellum in men with schizophrenia. J Psychiaty Neurosci 25: 509-512.
100. Valenzuela MJ, Sachdev P (2001). Magnetic resonance spectroscopy in AD. Neurology 56: 592-598.
101. Vermathen P, Laxer KD, Schuff N, Matson GB, Weiner MW (2003). Evidence of neuronal injury outside the medial temporal lobe in temporal lobe epilepsy: N-acetylaspartate concentration reductions detected with multisection proton MR spectroscopic imaging-initial experience. Radiology 226: 195-202.
102. Vuori K, Kankaanranta L, Hakkinen AM, Gaily E, Valanne L, Granstrom ML et al (2004). Low-grade gliomas and focal cortical developmental malformations: differentiation with proton MR spectroscopy. Radiology 230: 703-708.
103. Weber-Fahr W, Ende G, Braus DF, Bachert P, Soher BJ, Henn FA et al (2002). A fully automated method for tissue segmentation and CSF-correction of proton MRSI metabolites corroborates abnormal hippocampal NAA in schizophrenia. Neuroimage 16: 49-60.
104. 1H-MR spectroscopy and gray matter volume of the anterior cingulate cortex in schizophrenia. Neuroreport 13: 2133-2137.
105. Yurgelun-Todd DA, Renshaw PF, Gruber SA, Waternaux C, Cohen BM (1996). Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls. Schizophr Res 19: 55-59.
106. Zimmerman RA, Wang ZJ (1997). The value of proton MR spectroscopy in pediatric metabolic brain disease. Am J Neuroradiol 18: 1872-1879.